Impact of mao’ljabn or cheese-water on primary hypertensio
- Conditions
- hypertension.Essential (primary) hypertension
- Registration Number
- IRCT20140519017756N34
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 112
Being in stage 1 hypertension (i.e., systolic blood pressure greater than or equal to 140, and diastolic blood pressure greater than or equal to 90 mmHg based on the new definition of the Joint National Committee-8
Being treated with blood pressure medication (one to a maximum of three drugs based on the protocol), but the patient’s blood pressure is uncontrolled and still in stage 1 hypertension
A minimum of one month passed from the onset of drug consumption
Body mass index below 30
Age between 18 and 80 years
Stage 2 or above according to hypertension classification of the Joint National Committee-VIII
Blood pressure greater than or equal to 110/180 mmHg
History of secondary hypertension (e.g., hyperaldosteronism, pheochromocytoma, renal artery stenosis, Cushing's syndrome)
Endocrine disruption symptoms such as renal failure, congestive heart failure, myocardial infarction, or cerebrovascular accidents from the 6 months prior to the study onset
The presence of any type of cardiac arrhythmia (such as second- or third-degree blocks)
Symptomatic heart valve disease (except for mitral valve prolapse)
Type 1 and type 2 diabetic patients
Clinically significant renal and hepatic dysfunction, i.e., creatinine greater than 1.5 times the maximum normal and alanine aminotransferase more than 3 times the normal maximum
Number of platelets less than -100,000 or partial thromboplastin time more than 1.5
Pregnancy or breastfeeding intentions
Known or potential allergy to the tested product
Participation in any other clinical trials at the same time or within the last 30 days
History of malignancy treated or untreated in the last 5 years
Chronic oral or intravenous treatment with corticosteroids
Serum potassium greater than 5.2 or less than 3.5 milliequivalents in the first visit
Consuming contraceptive pills or psychiatric drugs
History of drug abuse, alcohol abuse, etc.
Any disruption (medical or surgical) that can interfere with the study according to the investigator or another serious illness
The patient's inappropriate cooperation in the project or compromising the patient’s safety or the incidence of any potential adverse effect by the drug
Childbirth during the project
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Systolic and diastolic blood pressure. Timepoint: Every two weeks from the study onset to two weeks after intervention. Method of measurement: Sphygmomanometer.;Sleep quality. Timepoint: Every two weeks from the study onset to two weeks after intervention. Method of measurement: Pittsburgh Sleep Quality Index.
- Secondary Outcome Measures
Name Time Method Weight loss or gain. Timepoint: Every two weeks from the study onset to two weeks after intervention. Method of measurement: Digital scale.